Patten Scott B
Department of Community Health Sciences and Psychiatry, University of Calgary, 3330 Hospital Drive NW, Calgary, Alberta, Canada T2N 4N1.
Curr Drug Saf. 2006 May;1(2):143-50. doi: 10.2174/157488606776930562.
Interferons are employed in the management of multiple sclerosis, hepatitis C and certain malignancies. Neuropsychiatric toxicity can interfere with the successful use of these drugs.
This review was based on Medline literature searches, supplemented by bibliographical citations in identified papers. Information uncovered in the literature review was interpreted in light of related pharmacoepidemiological and psychiatric literature.
Interferon-associated neurotoxicity does not adhere closely to standard psychiatric syndromal and diagnostic definitions. Delirium, depression, non-specific symptoms related to sickness behavior and, rarely, manic and psychotic syndromes are all potential adverse events during interferon treatment. For depression, the evidence of increased risk is stronger for interferon alpha than for interferon beta. The availability of preventive and treatment interventions suggest that neuropsychiatric toxicity can often be managed without needing to discontinue the treatment.
Safety can be maximized by organization of health services in ways that enhance detection and management of neuropsychiatric problems, and which support access to basic and specialized mental health services.
干扰素用于治疗多发性硬化症、丙型肝炎和某些恶性肿瘤。神经精神毒性会干扰这些药物的成功使用。
本综述基于对医学文献数据库（Medline）的文献检索，并辅以已识别论文中的参考文献。根据相关的药物流行病学和精神病学文献对文献综述中发现的信息进行解读。
与干扰素相关的神经毒性并不严格符合标准的精神综合征和诊断定义。谵妄、抑郁、与疾病行为相关的非特异性症状，以及罕见的躁狂和精神病综合征都是干扰素治疗期间的潜在不良事件。对于抑郁症，干扰素α导致风险增加的证据比干扰素β更强。预防性和治疗性干预措施的可用性表明，神经精神毒性通常可以在不停用治疗的情况下得到处理。
通过以加强神经精神问题的检测和管理、支持获得基本和专门心理健康服务的方式组织卫生服务，可以最大限度地提高安全性。
